Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALTNASDAQ:KALVNASDAQ:LRMRNASDAQ:VERV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$8.01-10.0%$8.33$2.09▼$14.84$567.93M0.223.11 million shs4.04 million shsKALVKalVista Pharmaceuticals$11.92-1.2%$11.74$7.21▼$16.88$502.88M0.92276,964 shs337,564 shsLRMRLarimar Therapeutics$7.38-0.7%$7.52$2.18▼$13.68$470.86M0.96275,446 shs284,266 shsVERVVerve Therapeutics$5.98-6.3%$8.99$5.84▼$21.42$502.11M1.941.27 million shs2.19 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune0.00%+10.94%+16.26%-8.56%+74.13%KALVKalVista Pharmaceuticals0.00%-1.32%+3.65%-19.78%+15.84%LRMRLarimar Therapeutics0.00%+3.65%+15.67%-42.25%+100.00%VERVVerve Therapeutics0.00%-0.50%-10.21%-54.32%-65.11%Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short videoMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune0.9685 of 5 stars3.31.00.00.01.81.70.0KALVKalVista Pharmaceuticals3.9358 of 5 stars3.52.00.04.61.81.70.6LRMRLarimar Therapeutics1.3801 of 5 stars3.51.00.00.02.71.70.0VERVVerve Therapeutics2.6307 of 5 stars3.40.00.00.03.15.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune2.60Moderate Buy$17.25115.36% UpsideKALVKalVista Pharmaceuticals3.00Buy$25.00109.73% UpsideLRMRLarimar Therapeutics3.00Buy$20.00171.00% UpsideVERVVerve Therapeutics2.75Moderate Buy$33.00451.84% UpsideCurrent Analyst RatingsLatest LRMR, VERV, ALT, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/10/2024ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$25.00 ➝ $24.005/9/2024VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/3/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.005/1/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/29/2024ALTAltimmuneGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/8/2024VERVVerve TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/3/2024LRMRLarimar TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/3/2024LRMRLarimar TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$25.004/3/2024VERVVerve TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $40.00(Data available from 5/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$430K1,320.72N/AN/A$2.44 per share3.28KALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/ALRMRLarimar TherapeuticsN/AN/AN/AN/A$3.62 per shareN/AVERVVerve Therapeutics$11.76M42.69N/AN/A$6.94 per share0.86Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.59N/AN/AN/A-22,645.37%-46.96%-42.96%8/8/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)LRMRLarimar Therapeutics-$36.95M-$0.97N/AN/AN/AN/A-35.69%-32.21%8/8/2024 (Estimated)VERVVerve Therapeutics-$200.07M-$2.87N/AN/AN/A-1,226.51%-37.35%-29.31%8/8/2024 (Estimated)Latest LRMR, VERV, ALT, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024ALTAltimmune-$0.36-$0.34+$0.02-$0.34N/A$0.01 million 5/9/2024Q1 2024LRMRLarimar Therapeutics-$0.24-$0.27-$0.03-$0.27N/AN/A5/8/2024Q1 2024VERVVerve Therapeutics-$0.70-$0.59+$0.11-$0.59$2.11 million$5.70 million3/27/2024Q4 2023ALTAltimmune-$0.35-$0.33+$0.02-$0.12N/A$0.04 million3/14/2024Q4 2023LRMRLarimar Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/A2/27/2024Q4 2023VERVVerve Therapeutics-$0.83-$0.69+$0.14-$0.69$3.95 million$5.14 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AVERVVerve TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.5516.55KALVKalVista PharmaceuticalsN/A5.445.44LRMRLarimar TherapeuticsN/A17.9917.99VERVVerve TherapeuticsN/A19.8219.82OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%KALVKalVista PharmaceuticalsN/ALRMRLarimar Therapeutics91.92%VERVVerve Therapeutics97.11%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%KALVKalVista Pharmaceuticals12.30%LRMRLarimar Therapeutics4.30%VERVVerve Therapeutics21.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5970.90 million68.00 millionOptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableLRMRLarimar Therapeutics4263.80 million61.06 millionOptionableVERVVerve Therapeutics25583.96 million66.00 millionOptionableLRMR, VERV, ALT, and KALV HeadlinesRecent News About These CompaniesMay 19 at 11:00 AM | accesswire.comIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmMay 19 at 6:22 AM | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Down 3.6% May 18 at 11:00 AM | accesswire.comIMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmMay 17 at 9:00 PM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Nikko Asset Management Americas Inc.May 17 at 3:53 PM | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Down 3.6%May 17 at 12:15 PM | accesswire.comIMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmMay 17 at 6:27 AM | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 17 at 6:04 AM | insidertrades.comAndrew D. Ashe Buys 76,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockMay 17 at 2:26 AM | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up After Insider Buying ActivityMay 16 at 11:45 AM | accesswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmMay 16 at 10:54 AM | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Shares Gap Up Following Insider Buying ActivityMay 15, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Andrew D. Ashe Acquires 76,000 SharesMay 15, 2024 | accesswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmMay 13, 2024 | bovnews.comDoes Verve Therapeutics Inc (VERV) Stock have a positive outlook following recent trade?May 13, 2024 | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 13, 2024 | americanbankingnews.comWilliam Blair Weighs in on Verve Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VERV)May 13, 2024 | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) to Post Q2 2024 Earnings of ($0.63) Per Share, HC Wainwright ForecastsMay 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 12, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Verve Therapeutics (NASDAQ:VERV)May 11, 2024 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong FinancialsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Nancy Pelosi Has Been BuyingMay 10, 2024 8:35 AMView 3 Stocks Nancy Pelosi Has Been Buying3 Affordable Stocks That Won’t Stay Down Much LongerMay 13, 2024 9:12 AMView 3 Affordable Stocks That Won’t Stay Down Much LongerHigher Oil Prices Could Give NextEra’s Stock Earnings a BoostApril 24, 2024 10:40 AMView Higher Oil Prices Could Give NextEra’s Stock Earnings a BoostWhat Wall Street Doesn’t Want You to Know About Alibaba StockMay 14, 2024 9:55 AMView What Wall Street Doesn’t Want You to Know About Alibaba StockCVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?April 30, 2024 9:25 AMView CVS Stock is Nearing a 52-Week Low, Better Buy Than Walgreens?All HeadlinesCompany DescriptionsAltimmuneNASDAQ:ALTAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Larimar TherapeuticsNASDAQ:LRMRLarimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Verve TherapeuticsNASDAQ:VERVVerve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.